April 2020 Vol 11, No 4
At the time I am writing this, we are in an unprecedented situation with
COVID-19 declared a global pandemic. As healthcare professionals, we have an
obligation to help our patients understand the risks and the ways in which they can
avoid contracting COVID-19.
This study examined characteristics of the Patient Care Connect Program team as an exemplar given their demonstrated success in improving patient health and care experience while lowering costs of care through patient navigation.
Nurse Navigator Debra Kelly describes her team’s experience in determining content and designing a guide to educate patients and improve their experience.
When elotuzumab was given in
combination with pomalidomide,
bortezomib, and dexamethasone
(elo-PVD), patients with
multiple myeloma refractory to prior
treatment demonstrated encouraging responses,
according to data from a phase 2
trial presented at the 2019 ASH Annual
Meeting by Andrew Yee, MD, from Massachusetts
General Hospital Cancer
Center in Boston.
In patients with multiple myeloma who were pomalidomide
naive and refractory to lenalidomide, an alloral
combination of selinexor, pomalidomide, and
dexamethasone (SPd) led to a median progression-free
survival (PFS) of 12.2 months and an overall response
rate (ORR) of 56%, with 19% of patients achieving very
good partial responses.
In patients with transplant-ineligible, newly diagnosed
multiple myeloma, adding daratumumab to
bortezomib, melphalan, and prednisone (D-VMP)
continues to improve overall survival (OS) and progression-free survival (PFS) when compared with bortezomib,
melphalan, and prednisone (VMP) alone.
Following induction therapy with
daratumumab (DARA) plus cyclophosphamide,
bortezomib, and
dexamethasone (CyBorD), monthly daratumumab
maintenance therapy given
for a year continued to improve depth of
response in a group of patients with newly
diagnosed or relapsed multiple myeloma.
In patients with relapsed or refractory
multiple myeloma, the efficacy benefits
seen when elotuzumab was added to
lenalidomide/dexamethasone (Ld) were
achieved without negatively affecting
health-related quality of life (HRQoL).
After more than 4 years of follow-up, the addition of daratumumab
to lenalidomide and
dexamethasone (D-Rd) continues to significantly
improve progression-free survival
(PFS) in patients with relapsed or
refractory multiple myeloma, according
to an update of the phase 3 POLLUX
study. Patients on D-Rd also demonstrated
deeper responses than patients who
received lenalidomide and dexamethasone
(Rd) alone.
In patients with newly diagnosed multiple myeloma,
treatment with weekly daratumumab plus carfilzomib,
lenalidomide, and dexamethasone (KRd) resulted in
an “unprecedented” minimal residual disease (MRD)
negativity rate of 77% without stem cell transplantation.
Payers and hospital systems can benefit tremendously through enhanced patient experience, clinical outcomes, and return on investment that navigation programs provide.
Most people have heard of palliative care, but
few truly know the meaning. Palliative care is
related to, but not the same as, hospice care.
In the United States, navigation is now an established
part of the healthcare system. But in other
countries it is still a brand-new concept, according
to Nancy Peña, OPN-CG, Founder and Director of
Navegación de Pacientes Internacional (NPI) in Guatemala
and oncology navigator at Dana-Farber/Brigham
and Women’s Cancer Center.
Results 1 - 13 of 13